Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

Next Previous
X
Search
Trial Profile

A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DFF 332 (Primary) ; Everolimus (Primary) ; Spartalizumab (Primary) ; Taminadenant (Primary)
  • Indications Leiomyoma; Paraganglioma; Phaeochromocytoma; Renal cell carcinoma; Von Hippel-Lindau disease
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 23 Jul 2024 Planned End Date changed from 28 Feb 2025 to 24 Feb 2025.
    • 23 Jul 2024 Planned primary completion date changed from 28 Feb 2025 to 21 Feb 2025.
    • 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top